Roche (RHHBY) News Today

Roche Holding AG (OTCMKTS:RHHBY) is receiving support from new pipeline developments, although reduced earnings estimates and the long-term, milestone-based nature of its latest deal may limit the upside.

• Positive Sentiment: Roche agreed to license global rights to Rona Therapeutics’ ALK7-targeting RNA interference treatment for obesity and metabolic diseases. The deal could generate up to $1.16 billion in milestone payments, giving Roche access to a potentially important obesity-treatment platform and expanding its metabolic-disease pipeline. The payments are contingent on development and commercial milestones, so the full value is not guaranteed. Reuters article
• Positive Sentiment: Roche reported positive Phase III results for vamikibart, an eye-drug candidate, and the U.S. Food and Drug Administration accepted the biologics license application. The therapy showed sustained vision improvements, fewer retreatments and a favorable safety profile, advancing it toward potential U.S. approval and future commercial revenue. Zacks article
• Neutral Sentiment: Brokerages reportedly maintain a consensus price target of approximately $60 for Roche shares, suggesting analysts see additional value from current levels. However, the target reflects existing expectations and is not a new company catalyst. Brokerage target article
• Negative Sentiment: Erste Group Bank lowered its Roche EPS estimates for both fiscal 2026 and 2027, to $3.05 and $3.31, respectively, from $3.14 and $3.41. The revisions indicate somewhat weaker expected earnings growth, though the new 2026 estimate remains close to the broader consensus of $3.03. MarketBeat analyst estimates